



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Available online at  
**ScienceDirect**  
[www.sciencedirect.com](http://www.sciencedirect.com)

Elsevier Masson France  
**EM|consulte**  
[www.em-consulte.com/en](http://www.em-consulte.com/en)



## LETTER TO THE EDITOR

### Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?



To the Editor,

The COVID-19 pandemic poses a big challenge to government and public healthcare sectors worldwide. Patients with increased age and pre-existing illnesses have been recognized as populations at risk of infection and severe course of COVID-19 [1]. It is speculated that SARS-CoV-2 is not only infectious but may also cause multi-organ dysfunctions in humans [2]. Up to now, there are limited reports on liver function abnormalities during COVID-19 infections. At this point it remains unclear to what extent hepatic diseases should be considered as potential risk factors of COVID-19 severity and mortality.

The available studies that have measured the liver function markers among COVID-19 patients are presented in the Table 1. A very recent study included 417 patients reported 76.3% of liver test abnormalities and 21.5% of liver injury among hospitalized COVID-19 patients [2]. In that study serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) were significantly higher in severe patients (ICU admitted) within 2 weeks of hospitalization. The authors observed that patients with elevated liver enzymes in the hepatocyte category had an increasing trend for progression to severe disease course. Serum GGT, a diagnostic biomarker of cholangiocyte injury, was a few folds higher in severe patients [2]. In another study, AST was elevated in 62% of patients in the intensive care unit (ICU) compared to 25% of patients who were not in the ICU [3]. The prevalence of ALT and AST abnormalities were observed at least two times higher among severe patients than non-severe patients with SARS-CoV-2 infection [4]. Moreover, in a study including 1099 patients, more severe patients had elevated ALT levels than non-severe patients with the disease [5]. Furthermore, in another study, the incidence of AST abnormalities was lower among patients before the onset of symptoms than the patients diagnosed after the onset of symptoms [6]. Therefore, liver dysfunctions are more prevalent in severe COVID-19 patients.

In the previous studies, pre-existing liver conditions have not been outlined, while increased ALT, decreased platelet

counts and decreased albumin concentrations at the time of admission were associated with higher mortality [4], although not all these changes are independent risk factors. It remains unclear yet whether these alterations are an indicator of pre-existing liver disease with a more severe disease course, whether they rather reflect liver failure caused by the virus itself [1]. A high prevalence of liver test abnormalities in some studies, suggesting that liver injury in COVID-19 patients might be directly caused by the SARS-CoV-2 infection of liver cells [2,7]. Two new studies have shown that angiotensin-converting enzyme 2 (ACE2) is the key receptor for SARS-CoV-2 cell entry [8,9], which is mainly present in the heart and kidney and also expressed at a lower level in other tissues including colon and lung [10]. SARS-CoV-2 may bind to ACE2 positive cholangiocytes directly and causes hepatic injury [11], which may partially clarify the contribution of SARS-CoV-2 infection to the liver test abnormalities in COVID-19 patients [2]. It is also important to mention that other respiratory viruses cause similar elevation of liver test markers, which is thought to relate to hepatic damage from immune interactions involving intrahepatic Kupffer cells and cytotoxic T cells [7]. Therefore, further investigations would be worth to confirm the association between viral infection and liver failure in severe COVID-19 patients.

It is also possible that drugs used for the treatment are associated with liver damage in severe COVID-19 patients which could explain the large variations found across the various studies. Although, there is no evidence suggesting that liver test abnormalities are completely induced by the drugs used for the treatment of COVID-19 patients. However, it is considered that using of ACE-inhibitors and angiotensin II receptor blockers drugs may also interfere with liver function tests. In a recent study, a high prevalence of liver dysfunction was observed among patients who used ACE-Is/ARBs drugs at hospital admission, although the difference was not significant with those who did not use these drugs [2]. In the same study, the authors [2] observed that after admission, using drugs especially lopinavir and ritonavir contributed significantly to liver dysfunctions. These drugs increased the odds of liver injury (OR from 4.44 to 5.03, both  $P < 0.01$ ) among patients. In their investigation, the liver biopsy of a patient who died from the disease had elevated liver enzymes that could be partly of the

**Table 1** Prevalence of elevated liver enzymes from different COVID-19 studies.

| Reference | Group         | Patients (n) | % of patients with abnormal liver test         |
|-----------|---------------|--------------|--|
| [2]       | Severe        | 85           | ALT (82.3), AST (75.3), GGT (72.3), ALP (12.2) |
|           | Non-severe    | 233          | ALT (52.2), AST (26.9), GGT (39.1), ALP (10.5) |
| [12]      | Hospitalized  | 99           | ALT (28), AST (35)                             |
| [5]       | Hospitalized  | 1099         | ALT (21.3), AST (22.2)                         |
| [3]       | Severe        | 13           | 62   |
|           | Non-severe    | 28           | 25   |
| [6]       | Hospitalized  | 81           | 53   |
| [13]      | Severe        | 36           | Not known                                      |
|           | Non-severe    | 102          | Not known                                      |
| [14]      | Hospitalized  | 62           | 16.1   |
| [15]      | Survivors     | 20           | 30   |
|           | Non-survivors | 32           | 28   |
| [4]       | Severe        | 30           | ALT (16.7), AST (26.7)                         |
|           | Mild          | 61           | ALT (8.2), AST (16.4)                          |

Severe: patients admitted in the intensive care unit (ICU).

drugs used in treatment, and the observed liver dysfunction may be due to sepsis and shock [2]. Moreover, the use of antibiotics showed a significant association with liver injury in COVID-19 patients in the multivariate regression model; however, the association was not significant when the inverse probability weighting model was applied [2]. So, besides possible viral exposure and drug-induced toxicity, immune-mediated inflammation, such as cytokines storm and pneumonia-related hypoxia might be another mechanism of liver damage in COVID-19 patients; further studies should confirm these associations. To reduce the risk, it is important to evaluate the detrimental effects of certain drugs on liver injury during hospitalization of the COVID-19 patients. Patients with liver cirrhosis or liver cancer are at high risk of SARS-CoV-2 infection due to their systemic immunocompromised status. Therefore, it is suggested to care for COVID-19 patients with chronic liver disease with priorities even in the limited healthcare resources. Large-scale clinical studies are needed to identify the causes of liver injury in the severe disease course and the effects of pre-existing liver disease on treatment and clinical outcome of COVID-19.

## Funding

None.

## Disclosure of interest

The author declares that he has no competing interest.

## References

- [1] Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. *JHEP Reports* 2020;2:100113, <http://dx.doi.org/10.1016/j.jhepr.2020.100113>.
- [2] Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. *J Hepatol* 2020, <http://dx.doi.org/10.1016/j.jhep.2020.04.006>. S01682782030218X.
- [3] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395:497–506, [http://dx.doi.org/10.1016/S0140-6736\(20\)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5).
- [4] Zhao X-Y, Xu X-X, Yin H-S, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. *BMC Infect Dis* 2020;20:311, <http://dx.doi.org/10.1186/s12879-020-05010-w>.
- [5] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;382:1708–20, <http://dx.doi.org/10.1056/NEJMoa2002032>.
- [6] Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020;20:425–34, [http://dx.doi.org/10.1016/S1473-3099\(20\)30086-4](http://dx.doi.org/10.1016/S1473-3099(20)30086-4).
- [7] Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020;5:428–30, [http://dx.doi.org/10.1016/S2468-1253\(20\)30057-1](http://dx.doi.org/10.1016/S2468-1253(20)30057-1).
- [8] Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* 2020;367:1444–8, <http://dx.doi.org/10.1126/science.abb2762>.
- [9] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;181:271–80, <http://dx.doi.org/10.1016/j.cell.2020.02.052>, e8.
- [10] Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. *Int J Hypertens* 2012, <http://dx.doi.org/10.1155/2012/307315>, 307315.
- [11] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv* 2020.
- [12] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;395:507–13, [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7).
- [13] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus–infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061, <http://dx.doi.org/10.1001/jama.2020.1585>.

- [14] Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020:m606, <http://dx.doi.org/10.1136/bmj.m606>.
- [15] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Resp Med* 2020, [http://dx.doi.org/10.1016/S2213-2600\(20\)30079-5](http://dx.doi.org/10.1016/S2213-2600(20)30079-5). S2213260020300795.

Nurshad Ali

*Department of Biochemistry and Molecular Biology,  
Shahjalal University of Science and Technology, Sylhet  
3114, Bangladesh*

*E-mail addresses: [nur.rubd@yahoo.com](mailto:nur.rubd@yahoo.com),  
[nali-bmb@sust.edu](mailto:nali-bmb@sust.edu)*

Available online 21 May 2020